Leads Biolabs’ Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.
NANJING, China, June 2, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on…
